Conversely, the ImmunoCobiVem study (ClinicalTrials.gov identifier: NCT02902029) aimed to investigate atezolizumab, a PD-L1 inhibitor, after initial doses of vemurafenib plus cobimetinib for advanced melanoma with the BRAFV600 mutation to achieve more prolonged survival. This evidence concerns the gene CD274 and melanoma.